Philip Agop Philip, MD, PhD, FRCP | Authors

Are We Ready for Neoadjuvant Therapy in Potentially Resectable Pancreatic Cancer?

February 18, 2011

Dr Castellanos et al have provided a very comprehensive review of the multimodality therapy of localized pancreatic cancer, with an emphasis on adjuvant and neoadjuvant therapies.

Gastric Carcinoma

April 01, 2005

Despite an overall rise in the incidence of gastrointestinal malignancies in the United States, there has been a significant decrease in the incidence of adenocarcinoma of the stomach over the past few decades. Nevertheless, gastric carcinoma remains the eighth leading cause of cancer death in the United States [1].

Carcinoma of the Esophagus

April 01, 2005

Carcinoma of the esophagus or the gastroesophageal junction is uncommon, accounting for approximately 1% of all malignancies in the United States [1]. An estimated 12,100 new cases and 10,900 deaths will occur in 1995.

Gemcitabine and UFT Plus Oral Calcium Folinate: Phase I Study

July 01, 1999

Gemcitabine (Gemzar) (2-deoxy-2,2-difluorocytidine) is a new antimetabolite being increasingly used in the treatment of solid tumors. It is an analog of deoxycytidine and cytosine arabinoside (Ara-C) (Figure 1) that has shown significant activity